This is an early access version
Study Program of Clinical Pathology, Faculty of Medicine, Universitas Airlangga , Surabaya , Indonesia
Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga , Surabaya , Indonesia
Department of Clinical Pathology, Dr. Soetomo General Academic Hospital , Surabaya , Indonesia
Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga , Surabaya , Indonesia
Department of Clinical Pathology, Dr. Soetomo General Academic Hospital , Surabaya , Indonesia
Aim To evaluate 3 point-of-care testing (POCT) devices in testing HbA1c: the Simplex TASTM101 (Tascom Co. Ltd., South Korea), which utilizes an enzymatic method, and two immunoassay-based devices, the Zybio Q8 Pro and Zybio EXR 110 (Zybio Inc., China).
Methods A total of 40 whole blood samples with EDTA anticoagulant were collected patients undergoing HbA1c testing at the outpatient department. The samples were analyzed using 3 POCT devices and one reference method.
Results Passing-Bablok regression revealed no significant fixed or proportional bias. Strong correlations with the gold standard were observed for Simplex TASTM101 (r=0.944), Zybio Q8 Pro (r=0.910), and Zybio EXR 110 (r=0.839), all with p<0.001. Bland-Altman analysis confirmed that the majority of measurements fell within an acceptable clinical range.
Conclusion This study demonstrated that the three POCT devices employing enzymatic and immunoassay methods served as reliable alternatives to ion exchange-high-performance liquid chromatography (IE-HPLC) for HbA1c measurement in clinical practice.
Conceptualization, W.R.A., F.R.M. and Y.P.; Data curation, W.R.A., F.R.M. and Y.P.; Formal Analysis, W.R.A., F.R.M. and Y.P.; Methodology, W.R.A., F.R.M. and Y.P.; Project administration, W.R.A. and Y.P.; Software, W.R.A. and F.R.M.; Validation, W.R.A., F.R.M. and Y.P.; Writing – original draft, W.R.A. and Y.P.; Writing – review & editing, W.R.A. and Y.P.; Funding acquisition, F.R.M. and Y.P.; Investigation, Y.P.; Resources, Y.P.; Supervision, Y.P.; Visualization, Y.P. All authors have read and agreed to the published version of the manuscript.
Although this study was supported by several provider, but the sponsor had no influence on the study design, data collection, analysis, interpretation, or the preparation of this manuscript.
This study was supported by funding from PT Saba Indomedika, the provider of the SimplexTASTM101 and PT Zybio Medical Indonesia, the provider of the Zybio series.
This work is licensed under a Attribution-NonCommercial-NoDerivatives 4.0 International 
0
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.